HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
BENZINGA
Jul-19-2024 6:41 a.m. ET
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (PHAT) with a Buy and maintains $28 price target.